American Heart Association Ventures Announces Investment in Healthtech Company MDisrupt

**American Heart Association Ventures Announces Investment in Healthtech Company MDisrupt**

*October 2023* – In a strategic move aimed at advancing healthcare innovation and improving patient outcomes, the American Heart Association (AHA) Ventures has announced its investment in MDisrupt, a rapidly growing healthtech company. This partnership underscores the AHA’s commitment to fostering cutting-edge solutions that can transform the landscape of cardiovascular care and public health.

### **About the American Heart Association Ventures**

The American Heart Association (AHA) is a leading nonprofit organization dedicated to fighting heart disease and stroke, the two leading causes of death globally. With a mission to build healthier lives free from cardiovascular diseases and stroke, the AHA has long been at the forefront of research, education, and advocacy.

AHA Ventures, the investment arm of the organization, was established to accelerate the development of innovative health technologies that align with the AHA’s mission. By investing in early-stage companies with promising solutions, AHA Ventures aims to bridge the gap between scientific discovery and real-world application, ensuring that groundbreaking technologies reach the patients who need them most.

### **MDisrupt: A Pioneer in Healthtech**

MDisrupt is a healthtech company that specializes in helping digital health companies bring clinically and scientifically validated products to market. Founded by healthcare experts, MDisrupt’s mission is to democratize access to healthcare innovation by ensuring that new technologies are evidence-based, safe, and effective.

The company’s unique platform connects digital health startups with a network of healthcare professionals, scientists, and regulatory experts who can guide them through the complex process of clinical validation, regulatory approval, and market entry. MDisrupt’s approach is designed to help healthtech companies avoid common pitfalls, such as lack of clinical evidence or regulatory hurdles, which can delay or derail product launches.

By focusing on the intersection of technology, science, and healthcare, MDisrupt is playing a pivotal role in shaping the future of digital health. The company’s expertise spans a wide range of areas, including diagnostics, remote monitoring, digital therapeutics, and wearable devices, all of which have the potential to revolutionize cardiovascular care.

### **The Significance of the Investment**

The investment by AHA Ventures in MDisrupt is significant for several reasons. First, it highlights the growing recognition of the importance of digital health technologies in addressing the global burden of cardiovascular disease. With heart disease remaining the leading cause of death in the United States, there is an urgent need for innovative solutions that can improve prevention, diagnosis, and treatment.

Second, the partnership aligns with the AHA’s broader strategy of leveraging technology to enhance patient care. Over the past decade, the AHA has increasingly embraced digital health tools, such as mobile apps, wearables, and telemedicine, as part of its efforts to promote heart health and reduce the incidence of cardiovascular disease. By investing in MDisrupt, the AHA is signaling its belief that the future of cardiovascular care lies in the integration of technology with traditional healthcare practices.

Third, the collaboration between AHA Ventures and MDisrupt has the potential to accelerate the development and adoption of new cardiovascular technologies. MDisrupt’s platform can help digital health companies navigate the regulatory landscape and ensure that their products are backed by robust clinical evidence. This, in turn, can increase the likelihood that these technologies will be adopted by healthcare providers and trusted by patients.

### **Potential Impact on Cardiovascular Care**

The investment in MDisrupt could have far-reaching implications for cardiovascular care. One of the key challenges in the field is the early detection and management of heart disease. Many patients are unaware that they are at risk until they experience a major event, such as a heart attack or stroke. Digital health technologies, such as wearable devices that monitor heart rate or blood pressure, have the potential to identify at-risk individuals earlier and enable timely interventions.

Additionally, digital therapeutics and remote monitoring tools can help patients with chronic cardiovascular conditions manage their health more effectively. For example, a patient with heart failure could use a remote monitoring device to track their symptoms and share data with their healthcare provider in real-time. This could lead to more personalized treatment plans and reduce the likelihood of hospital readmissions.

By investing in MDisrupt, the AHA is positioning itself to play a key role in the development and dissemination of these technologies. The partnership could also lead to new collaborations between MDisrupt and other stakeholders in the cardiovascular space, including healthcare providers, researchers, and pharmaceutical companies.

### **Looking Ahead: A Shared Vision for the Future**

Both the American Heart Association and MDisrupt share a common vision: to improve health outcomes through the responsible and effective use of technology. As the healthcare landscape continues to evolve, the integration of digital health tools will be critical to addressing the challenges posed by cardiovascular disease.

The investment in MDisrupt is just one example of how the AHA is embracing innovation to fulfill its mission. By supporting companies that prioritize clinical validation and patient